Gamma Oryzanol for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Gamma Oryzanol for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A rice bran compound, licensed in Japan for six decades. The most consistent human signal is modest lowering of total and plaque-forming cholesterol, delivered through rice bran oil. Side effects appear rare and mild. Absorption is the unresolved problem, and within a programme already addressing blood fats the expected contribution is small. (Full Review)

Protocol

Standard lipid dose
300 mg daily
The long-standing Japanese therapeutic dose. Published trials span 50–800 mg daily, with no consistent additional benefit above 300 mg.
Rice bran oil as the delivery vehicle
30 mL oil daily
Oil at 8,000–11,000 parts per million oryzanol, incorporated into cooked meals; the regimen that produced the largest controlled lipid reductions.
Best time of day
With the largest fat-containing meal
Uptake depends on the food matrix. Split dosing across meals mirrors Japanese practice of 100 mg three times daily.
Time to effect
Lipid changes
4 weeks
Lipid changes are measurable at four weeks.
Inflammation marker and glycated hemoglobin
12 weeks
Inflammation marker and glycated hemoglobin changes required twelve weeks in trials.
Skin hydration
4–8 weeks
Skin hydration effects emerged between weeks four and eight.

Benefits

Contraindications
  • Sitosterolemia, or homozygous/compound-heterozygous ABCG5 or ABCG8 loss-of-function
  • Documented rice or rice bran allergy
  • Under-active thyroid or other thyroid disease
  • Pregnancy and lactation at doses above ordinary dietary amounts
  • Significant renal impairment (filtration rate below 30 mL/min/1.73 m²) for whole rice bran preparations containing phytic acid
Key Interactions
  • Statins (atorvastatin, rosuvastatin, simvastatin)
  • Cholesterol absorption inhibitors (ezetimibe)
  • Bile acid sequestrants (cholestyramine, colesevelam)
  • Over-the-counter plant sterol and stanol products (fortified spreads, sterol tablets)
  • Over-the-counter fat-soluble vitamin and carotenoid products
  • Supplements with additive lipid effects (red yeast rice, berberine, psyllium fibre, plant stanol esters, niacin, marine omega-3 fatty acids)
  • Supplement combinations tested together (vitamin E, omega-3 fatty acids, niacin)
  • Brown rice-based diet
    •

Risk & Side Effects

  • High: Negligible absorption of the intact compound
    •
  • Medium: Substitution for established lipid-lowering treatment; contaminant load in crude rice bran products
  • Low: Suppression of pituitary hormone release; mild gastrointestinal, skin and autonomic side effects
  • Speculative: Reduced fat-soluble micronutrient absorption; tumor promotion at very high dietary doses

Monitoring

Marker Target Why
LDL cholesterol < 70 mg/dL aggressive; < 100 mg/dL minimum The primary documented effect; defines whether the compound is working
Apolipoprotein B < 60 mg/dL aggressive; < 80 mg/dL acceptable Counts every plaque-forming particle, so it tracks risk better than LDL cholesterol alone
Total cholesterol 150–200 mg/dL Second endpoint in every pooled analysis; moves in parallel with LDL cholesterol
Triglycerides < 80 mg/dL Fell significantly in two of three poolings and in the diabetes trial
High-density lipoprotein cholesterol > 50 mg/dL in men, > 60 mg/dL in women The one lipid fraction where a sex difference in response appeared
High-sensitivity C-reactive protein < 0.5 mg/L optimal; < 1.0 mg/L acceptable Showed the largest proportional change of any marker in controlled testing
Glycated hemoglobin 4.8–5.4% Captures the glucose effect seen in metabolic dysfunction
Fasting glucose 75–90 mg/dL Moved measurably in the diabetes trial; cheap and widely available
Thyroid-stimulating hormone 0.5–2.0 mIU/L The one hormone an oral dose has been shown to move in humans; flags the thyroid caution
Alanine aminotransferase < 25 U/L in men, < 20 U/L in women Confirms the liver tolerates the addition and detects unrelated change
Plasma sitosterol and campesterol No established target; track change from own baseline Identifies high sterol absorbers and screens for the inherited retention disorder

Cadence: Lipid panel at 4 and 12 weeks, then every 6–12 months if continued; inflammation marker and glycated hemoglobin at 12 weeks; thyroid-stimulating hormone at 12 weeks where thyroid disease is known.

Qualitative Assessment

  • Digestive comfort and stool consistency
  • Frequency and intensity of hot flushes
  • Skin dryness and comfort
  • Subjective energy and daytime alertness
  • Any new itching, rash, or swelling
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.